New staging system enhances prognosis accuracy for gastric cancer

A novel prognostic staging system developed from residual tumor burden significantly outperforms the AJCC’s YpTNM staging in predicting overall survival (OS) and recurrence-free survival (RFS) in patients with locally advanced gastric cancer post-neoadjuvant chemotherapy. The study analyzed data from 537 patients, finding that factors like lymph node stage and carcinoembryonic antigen levels were robust indicators of survival outcomes. The new model demonstrated improved 3-year OS and RFS stratification compared to established AJCC standards.